Table 1.
Characteristics of 28 874 patients undergoing HCT
| Characteristic | No. of patients | % |
|---|---|---|
| All patients | 28 874 | 100.0 |
| CIBMTR | 23 542 | 81.5 |
| FHCRC | 5 332 | 18.5 |
| Sex | ||
| Male | 17 122 | 59.3 |
| Female | 11 752 | 40.7 |
| Age at transplantation, y | ||
| 0-9 | 4 058 | 14.1 |
| 10-19 | 5 773 | 20.0 |
| 20-29 | 6 812 | 23.6 |
| 30-39 | 6 796 | 23.5 |
| 40-49 | 4 379 | 15.2 |
| 50 or older | 1 056 | 3.7 |
| Median | 27 | |
| (Min-Max) Range | (0.08-72.41) | |
| Geographic region of transplantation team | ||
| United States, Canada | 13 745 | 47.6 |
| Europe | 11 340 | 39.3 |
| Other | 3 789 | 13.1 |
| Primary disease | ||
| ALL | 5 916 | 20.5 |
| ANLL | 7 461 | 25.8 |
| CML | 7 594 | 26.3 |
| Other leukemia | 452 | 1.6 |
| NHL | 1 152 | 4.0 |
| HL | 242 | 0.8 |
| Myeloma | 507 | 1.8 |
| Other malignancies* | 158 | 0.5 |
| SAA | 2 842 | 9.8 |
| MDS, MPD | 1 298 | 4.5 |
| Hemoglobinopathies | 906 | 3.1 |
| Other | 346 | 1.2 |
| Donor-recipient relationship and histocompatibility | ||
| Identical twin | 631 | 2.2 |
| HLA-identical sibling | 22 030 | 76.3 |
| HLA-mismatched sibling, other relative | 2 939 | 10.2 |
| Unrelated donor | 3 066 | 10.6 |
| Other, uncertain (not autologous) | 208 | 0.7 |
| Transplant-conditioning regimens | ||
| TBI + Cy ± other drugs | 16 934 | 58.6 |
| TBI + other drugs (no Cy) | 2 409 | 8.3 |
| LFI ± Cy ± other drugs | 809 | 2.8 |
| Busulfan + Cy ± other drugs | 6 510 | 22.5 |
| Cy ± other drugs | 1 881 | 6.5 |
| Other | 331 | 1.1 |
| Preventative GVHD therapy | ||
| No T-cell depletion | ||
| CsA (no MTX) | 6 540 | 22.7 |
| MTX (no CsA) | 4 552 | 15.8 |
| CsA + MTX | 12 986 | 45.0 |
| Other | 1 023 | 3.5 |
| T-cell depletion | 3 726 | 12.9 |
| Unknown | 47 | 0.2 |
| Cumulative incidence of acute GVHD (grades II-IV), % | ||
| 100 d after transplantation | 38.2 | |
| 1 y after transplantation | 38.4 | |
| Cumulative incidence of chronic GVHD, %† | ||
| 1 y after transplantation | 28.9 | |
| 3 y after transplantation | 31.0 | |
| TBI dose | ||
| No TBI or LFI | 8 592 | 29.8 |
| Single dose | ||
| Less than 10 Gy | 1 934 | 6.7 |
| 10 Gy or more | 2 387 | 8.3 |
| Fractionated dose | ||
| Less than 12 Gy | 2 710 | 9.4 |
| 12 to less than 13 Gy | 7 122 | 24.7 |
| 13 to less than 14 Gy | 2 329 | 8.1 |
| 14 to less than 15 Gy | 1 528 | 5.3 |
| 15 Gy or more | 1 161 | 4.0 |
| Limited field irradiation, no TBI | 809 | 2.8 |
| Unknown TBI dose, other radiation | 302 | 1.0 |
Percentages do not always add up to 100% due to rounding.
ANLL indicates acute nonlymphocytic leukemia; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; MDS, myelodysplastic syndromes; MPD, myeloproliferative disorders; Cy, cyclophosphamide; CsA, cyclosporine; and MTX, methotrexate.
*
Other malignancies include 121 solid (nonbreast) cancers (primarily neuroblastoma and sarcomas), 3 breast cancers, and 34 other malignancies. See Table 2 for second malignancies among these patients.
†
Chronic GVHD is defined as clinical extensive disease for FHCRC patients and includes all grades of chronic GVHD for CIBMTR patients.